Reconsideration of the use of meningococcal polysaccharide vaccine.
In 2005, a quadrivalent meningococcal conjugate vaccine was licensed in the United States for persons aged 11-55 years of age. For children aged 2-10 years with underlying diseases associated with increased risk of meningococcal disease, unconjugated meningococcal polysaccharide (MPS) vaccination is...
Үндсэн зохиолчид: | Granoff, D, Pollard, A |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
2007
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Meningococcal polysaccharide-protein conjugate vaccines.
-н: Snape, MD, зэрэг
Хэвлэсэн: (2005) -
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
-н: Pace, D, зэрэг
Хэвлэсэн: (2007) -
Meningococcal polysaccharide-protein conjugate vaccines (vol 5, pg 21, 2005)
-н: Snape, MD, зэрэг
Хэвлэсэн: (2005) -
Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.
-н: Rolando Pajon, зэрэг
Хэвлэсэн: (2013-01-01) -
Meningococcal vaccines.
-н: Bethell, D, зэрэг
Хэвлэсэн: (2002)